Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors

August 2013 | 13 pages | ID: CEB848109E1EN
La Merie Publishing

Abstracts

The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of small molecule Bruton’s Tyrosine Kinase (BTK) inhibitors in oncology and inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of BTK inhibitors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About theCompetitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

• BTK Inhibitors in Oncology
• BTK Inhibitors in Inflammatory and Autoimmune Diseases
• Corporate BTK Inhibitor R&D Pipelines